TFA
BTAI icon

Toth Financial Advisory’s BioXcel Therapeutics BTAI Stock Holding History

Toth Financial Advisory’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-31
Closed -$305 – 706
2024
Q3 		$305 Hold
31
– – ﹤0.01% 697
2024
Q2 		$640 Hold
31
– – ﹤0.01% 718
2024
Q1 		$1.41K Hold
31
– – ﹤0.01% 653
2023
Q4 		$1.48K Hold
31
– – ﹤0.01% 654
2023
Q3 		$1.26K Buy
+31
New +$3.13K ﹤0.01% 696

Other funds holding BTAI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Toth Financial Advisory's BTAI Position: Q4 2024 in Review

Toth Financial Advisory sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 31 shares — an estimated $305 sold.

Toth Financial Advisory first reported a position in BTAI in Q3 2023 and held it in 5 quarters. The position peaked at $1.48K in Q4 2023. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

  • Toth Financial Advisory reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Toth Financial Advisory sold 31 BioXcel Therapeutics shares in Q4 2024, an estimated $305.
  • Toth Financial Advisory first reported a position in BioXcel Therapeutics in Q3 2023 and held it in 5 quarters.
  • Toth Financial Advisory's BioXcel Therapeutics position peaked at $1.48K in Q4 2023.
  • 49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on Toth Financial Advisory's 13F filing for Q4 2024, filed 21 Jan 2025.